Company intelligence / Profile preview

Oncko

Ownership: Private
Development stage: Preclinical

Overview

Oncko uses high-throughput combinatorial genomics technologies to discover the best combination therapies for cancer patients. The company’s approach leverages proprietary platforms such as Shuffle-seq and large-scale in vivo perturbation screens. No clinical results have been published yet; efforts are focused on preclinical discovery and validation.

Therapeutic areas: Oncology
Modalities: Small moleculesdrug combinations (focus on combination therapies for cancer)
Industry: Biotech

Drug pipeline

3 assets

Combo #1

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships disclosed as of May 2025

Beyond the preview

Go deeper on Oncko.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncko.

Explore the full profile